The Beijing Angle Closure Progression Study
ConditionAngle-Closure Glaucoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-75
SponsorPeking University People's Hospital
About this trial
The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
"Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field.
Able to provide informed consent
Disqualifiers
Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP > 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy).
Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty
Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy.
Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor.
Trial population
Patients with primary angle-closure suspect who agree to take part in this trial were given a comprehensive baseline examination and who decline will be asked for a reason. Verbal and written informed consent was obtained from every patient. A comprehensive baseline examination will be done for every enrolled subjects. Patients are monitored for 5 years. All examinations that may be related to subjective judgment and manipulation, i.e. Goldmann applanation (GAT), ultrasound biomicroscopy (UBM), gonioscopy, are performed by experienced examiner.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
825 Participants
are grouped into 2 trial groupsGroup A: progression group
Group B: non-progression group
Trial outcomes
Primary outcomes
1
the progression rate 1
the rate of acute angle closureanterior synechiae
Time frame
6 months2
the progression rate 2
the proportion of eyes developing peripheral
Time frame
6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov